報價延遲最少15分鐘:2026/09/04 00:11 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.08 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.60/-0.57
|
|
企業價值
82.56M
|
| 資產負債 |
|
每股賬面淨值
0.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
593.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigationin other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients. |
